KV Pharmaceutical Company (NYSE: KVa/KVb) announced that it has received approval from the U.S. Food and Drug Administration (FDA) on its application for the 100 mg and 200 mg strengths of Morphine ER Tablets (MS Contin(R) marketed by Purdue Pharma L.P.). This approval now allows ETHEX Corporation, KV’s wholly-owned generic/non-branded subsidiary, to offer a full line of all strengths of this product. [click link for full article]

More: continued here

This entry was posted on Friday, October 26th, 2007 at 2:10 pm and is filed under Pain / Anesthetics. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.